TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Fujirebio Diagnostics AB
Closing information (x1000 SEK)
| Closing information | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) | 
| Turnover | 321,181 | 310,881 | 265,132 | 
| Financial expenses | 4,335 | 84 | 474 | 
| Earnings before taxes | 167,766 | 177,420 | 139,372 | 
| EBITDA | 173,284 | 183,880 | 144,735 | 
| Total assets | 774,677 | 644,594 | 615,270 | 
| Current assets | 476,219 | 335,504 | 296,982 | 
| Current liabilities | 121,458 | 49,799 | 63,557 | 
| Equity capital | 645,010 | 587,142 | 545,028 | 
| - share capital | 641   | 641   | 641 | 
| Employees (average) | 89 | 86 | 75 | 
Financial ratios
| Fiscal year | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) | 
| Solvency | 83.3% | 91.1% | 88.6% | 
| Turnover per employee | 3,609 | 3,615 | 3,535 | 
| Profit as a percentage of turnover | 52.2% | 57.1% | 52.6% | 
| Return on assets (ROA) | 22.2% | 27.5% | 22.7% | 
| Current ratio | 392.1% | 673.7% | 467.3% | 
| Return on equity (ROE) | 26.0% | 30.2% | 25.6% | 
| Change turnover | 10,300 | 45,749 | 14,911 | 
| Change turnover % | 3% | 17% | 6% | 
| Chg. No. of employees | 3 | 11 | 4 | 
| Chg. No. of employees % | 3% | 15% | 6% | 
Total value of public sale
| Fiscal year | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) | 
| Total value of public sale | 0   | 0   | 0 | 
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.
 
         
                    